Ratings VITA 34 AG

Equities

V3V

DE000A0BL849

Real-time Estimate Tradegate Other stock markets 03:30:00 2024-05-03 am EDT			5-day change	1st Jan Change
4.74 ^EUR	-0.42%		-5.74%	-9.16%

2023	VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
VITA 34 AG	-9.16%	88.77M	-
HCA HEALTHCARE, INC.	+14.10%	81.68B	C+
CVS HEALTH CORPORATION	-30.15%	69.23B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	29.08B	C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.90%	16.88B	B
FRESENIUS SE & CO. KGAA	-0.07%	16.85B	A-
QUEST DIAGNOSTICS INCORPORATED	-1.12%	15.15B	A-
FRESENIUS MEDICAL CARE AG	+5.61%	12.62B	A-
DAVITA INC.	+35.78%	12.47B	B-
EUROFINS SCIENTIFIC SE	-3.87%	11.66B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes